Emerging Biopharma

>

Latest News

Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug
Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug

March 25th 2025

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China.

Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist

March 25th 2025

Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion

March 20th 2025

Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and Musculoskeletal Care Innovations
Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and Musculoskeletal Care Innovations

March 19th 2025

Emerging Biopharma Launches: Strategizing in Today’s Global Market
Emerging Biopharma Launches: Strategizing in Today’s Global Market

March 13th 2025

More News